EVMN PE Ratio & Valuation,Is EVMN Overvalued

EVMN Relative Valuation

EVMN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EVMN is overvalued; if below, it's undervalued.

Historical Valuation

Evommune Inc (EVMN) is now in the Overvalued zone, suggesting that its current forward PS ratio of 327.40 is considered Overvalued compared with the five-year average of -5.83. The fair price of Evommune Inc (EVMN) is between 15.24 to 17.39 according to relative valuation methord. Compared to the current price of 18.23 USD , Evommune Inc is Overvalued By 4.8%.

Relative Value

Fair Zone

15.24-17.39

Current Price：18.23

4.8%

Overvalued

-5.38

-7.05

EV/EBITDA

Evommune Inc. (EVMN) has a current EV/EBITDA of -7.05. The 5-year average EV/EBITDA is -7.26. The thresholds are as follows: Strongly Undervalued below -7.99, Undervalued between -7.99 and -7.63, Fairly Valued between -6.89 and -7.63, Overvalued between -6.89 and -6.53, and Strongly Overvalued above -6.53. The current Forward EV/EBITDA of -7.05 falls within the Historic Trend Line -Fairly Valued range.

-7.32

EV/EBIT

Evommune Inc. (EVMN) has a current EV/EBIT of -7.32. The 5-year average EV/EBIT is -7.54. The thresholds are as follows: Strongly Undervalued below -8.30, Undervalued between -8.30 and -7.92, Fairly Valued between -7.16 and -7.92, Overvalued between -7.16 and -6.78, and Strongly Overvalued above -6.78. The current Forward EV/EBIT of -7.32 falls within the Historic Trend Line -Fairly Valued range.

327.40

Evommune Inc. (EVMN) has a current PS of 327.40. The 5-year average PS is 344.09. The thresholds are as follows: Strongly Undervalued below 295.83, Undervalued between 295.83 and 319.96, Fairly Valued between 368.22 and 319.96, Overvalued between 368.22 and 392.35, and Strongly Overvalued above 392.35. The current Forward PS of 327.40 falls within the Historic Trend Line -Fairly Valued range.

-5.93

P/OCF

Evommune Inc. (EVMN) has a current P/OCF of -5.93. The 5-year average P/OCF is -6.23. The thresholds are as follows: Strongly Undervalued below -7.11, Undervalued between -7.11 and -6.67, Fairly Valued between -5.80 and -6.67, Overvalued between -5.80 and -5.36, and Strongly Overvalued above -5.36. The current Forward P/OCF of -5.93 falls within the Historic Trend Line -Fairly Valued range.

-5147.94

P/FCF

Evommune Inc. (EVMN) has a current P/FCF of -5147.94. The 5-year average P/FCF is -5410.33. The thresholds are as follows: Strongly Undervalued below -6169.19, Undervalued between -6169.19 and -5789.76, Fairly Valued between -5030.90 and -5789.76, Overvalued between -5030.90 and -4651.47, and Strongly Overvalued above -4651.47. The current Forward P/FCF of -5147.94 falls within the Historic Trend Line -Fairly Valued range.

Evommune Inc (EVMN) has a current Price-to-Book (P/B) ratio of -0.15. Compared to its 3-year average P/B ratio of -0.16 , the current P/B ratio is approximately -7.66% higher. Relative to its 5-year average P/B ratio of -0.16, the current P/B ratio is about -7.66% higher. Evommune Inc (EVMN) has a Forward Free Cash Flow (FCF) yield of approximately -14.36%. Compared to its 3-year average FCF yield of -13.74%, the current FCF yield is approximately 4.58% lower. Relative to its 5-year average FCF yield of -13.74% , the current FCF yield is about 4.58% lower.

-0.15

P/B

Median3y

-0.16

Median5y

-0.16

-14.36

FCF Yield

Median3y

-13.74

Median5y

-13.74

Competitors Valuation Multiple

The average P/S ratio for EVMN's competitors is 77.50, providing a benchmark for relative valuation. Evommune Inc Corp (EVMN) exhibits a P/S ratio of 327.40, which is 322.44% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of EVMN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of EVMN in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Evommune Inc (EVMN) currently overvalued or undervalued?

What is Evommune Inc (EVMN) fair value?

EVMN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Evommune Inc (EVMN) is between 15.24 to 17.39 according to relative valuation methord.

How does EVMN's valuation metrics compare to the industry average?

What is the current P/B ratio for Evommune Inc (EVMN) as of Jan 08 2026?

As of Jan 08 2026, Evommune Inc (EVMN) has a P/B ratio of -0.15. This indicates that the market values EVMN at -0.15 times its book value.

What is the current FCF Yield for Evommune Inc (EVMN) as of Jan 08 2026?

As of Jan 08 2026, Evommune Inc (EVMN) has a FCF Yield of -14.36%. This means that for every dollar of Evommune Inc’s market capitalization, the company generates -14.36 cents in free cash flow.

What is the current Forward P/E ratio for Evommune Inc (EVMN) as of Jan 08 2026?

As of Jan 08 2026, Evommune Inc (EVMN) has a Forward P/E ratio of -5.38. This means the market is willing to pay $-5.38 for every dollar of Evommune Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Evommune Inc (EVMN) as of Jan 08 2026?

As of Jan 08 2026, Evommune Inc (EVMN) has a Forward P/S ratio of 327.40. This means the market is valuing EVMN at $327.40 for every dollar of expected revenue over the next 12 months.

EVMN Valuation